费城染色体阳性急性淋巴细胞性白血病(Philadelphia-positive acute lymphoblastic leukemia,Ph+ALL)既往一直被视为是ALL中预后较差的亚型。人群总发病率20%,随着年龄的增加,从儿童5%到成人25%~(〔1〕)。单用化疗的完全缓解率(CR)至少比Ph阴性的ALL低10%,中位生存8个月左右,5年无事件生存率(EFS)<20%~(〔2〕)。近10年来,酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)的引入使几乎所有的患者获得完全 Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) has long been considered as a poorer subtype of ALL. The total incidence of the population is 20%, with the increase of age, from 5% of children to 25% of adults ([1]). The complete response rate (CR) of chemotherapy alone was at least 10% lower than that of Ph-negative ALL, median survival was about 8 months, and 5-year event-free survival (EFS) was <20% ([2]). In the past 10 years, the introduction of tyrosine kinase inhibitors (TKIs) has made it almost complete for almost all patients.